Perspective Therapeutics Share Price Today
(NASDAQ: CATX)

Name: Perspective Therapeutics Share Price Today (NASDAQ: CATX) - Perspective Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Perspective Therapeutics share price is $1.94 & ₹165.80 as on 18 Apr 2025, 2.30 'hrs' IST

$1.94

▲

0.09

(4.86%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Perspective Therapeutics share price in Dollar and Rupees. Guide to invest in Perspective Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Perspective Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Perspective Therapeutics share price movements

Today's Low: $1.75
Today's High: $1.94
$1.94
9.79%
Downside
Day's Volatility :9.79%
Upside
0.0%
52 Weeks Low: $1.60
52 Weeks High: $19.05
$1.94
17.53%
Downside
52 Weeks Volatility :91.6%
Upside
89.82%

Perspective Therapeutics (CATX) Returns

Period	Perspective Therapeutics Inc.	Index (Russel 2000)
3 Months	-44.89%	0.0%
6 Months	-84.72%	0.0%
1 Year	-87.07%	0.0%
3 Years	-48.95%	-12.9%

Perspective Therapeutics (CATX) Key Statistics

in dollars & INR

Previous Close	$1.85
Open	$1.85
Today's High	$1.94
Today's Low	$1.75
Market Capitalization	$143.7M
Today's Volume	$807.0K
52 Week High	$19.05
52 Week Low	$1.6
Revenue TTM	$1.5M
EBITDA	$-64.5M
Earnings Per Share (EPS)	$-1.22
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-42.82%

How to invest in Perspective Therapeutics Stock (CATX) from India?

It is very easy for Indian residents to invest directly in Perspective Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Perspective Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Perspective Therapeutics or CATX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Perspective Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Perspective Therapeutics shares which would translate to 0.441 fractional shares of Perspective Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Perspective Therapeutics, in just a few clicks!

Returns in Perspective Therapeutics (CATX) for Indian investors in Rupees

The Perspective Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Perspective Therapeutics investment value today

Current value as on today

₹15,274

Returns

₹84,726

(-84.73%)

Returns from Perspective Therapeutics Stock

₹87,067 (-87.07%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Perspective Therapeutics (CATX)

140%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Perspective Therapeutics Stock from India on INDmoney has increased by 140% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Perspective Therapeutics

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Perspective Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Perspective Therapeutics Stock (CATX)

What analysts predicted

Upside of 641.9%

Target:

$14.39

Current:

$1.94

Insights on Perspective Therapeutics Stock (Ticker Symbol: CATX)

Price Movement
In the last 6 months, CATX stock has moved down by -85.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.90M → 337.0K (in $), with an average decrease of 82.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -11.70M → -40.16M (in $), with an average decrease of 97.4% per quarter
CATX vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 41.5% return, outperforming this stock by 129.2%
Price to Sales
ForCATX every $1 of sales, investors are willing to pay $84.3, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Perspective Therapeutics Technicals Summary

Sell

Neutral

Buy

Perspective Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Perspective Therapeutics (CATX) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Perspective Therapeutics Inc.	-25.7%	-84.72%	-87.07%	-48.95%	-48.95%
Medtronic Plc	-9.34%	-9.26%	3.93%	-26.9%	-18.65%
Edwards Lifesciences Corp.	0.35%	2.11%	-16.77%	-44.23%	-4.46%
Boston Scientific Corp.	-6.17%	8.03%	41.27%	101.95%	155.36%
Stryker Corporation	-7.36%	-5.65%	6.47%	25.38%	87.58%
Abbott Laboratories	3.31%	11.96%	22.09%	6.8%	33.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Perspective Therapeutics Inc.	NA	NA	NA	-1.12	-0.43	-0.19	NA	4.11
Medtronic Plc	25.18	25.18	1.42	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	30.57	30.57	4.28	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	76.1	76.2	1.87	2.86	0.09	0.05	NA	14.76
Stryker Corporation	44.62	44.62	1.97	13.47	0.15	0.07	0.01	54.1
Abbott Laboratories	17.14	17.14	4.17	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Perspective Therapeutics Inc.	Buy	$143.7M	-48.95%	NA	0.0%
Medtronic Plc	Buy	$105.9B	-18.65%	25.18	12.83%
Edwards Lifesciences Corp.	Buy	$41.9B	-4.46%	30.57	76.75%
Boston Scientific Corp.	Buy	$140.7B	155.36%	76.1	11.07%
Stryker Corporation	Buy	$132.3B	87.58%	44.62	13.25%
Abbott Laboratories	Buy	$227.2B	33.65%	17.14	31.89%

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, engages in the development and commercialization of precision-targeted alpha therapies (TAT) in the United States It discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumours that have not previously received peptide targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Organization	Perspective Therapeutics
Employees	138
CEO	Mr. Johan M. Spoor
Industry	Miscellaneous

Management People of Perspective Therapeutics

Name	Title
Mr. Johan M. Spoor	CEO & Director
Mr. Jonathan R. Hunt	Chief Accounting Officer
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer
Mr. Juan Graham	Chief Financial Officer
Mr. Shane Cobb	Executive Vice President of Operations
Dr. Michael K. Schultz Ph.D.	Chief Science Officer
Ms. Annie J. Cheng	Vice President of Investor Relations

Important FAQs about investing in CATX Stock from India :

What is Perspective Therapeutics share price today?

Perspective Therapeutics share price today stands at $1.94, Open: $1.85 ; Previous Close: $1.85 ; High: $1.94 ; Low: $1.75 ; 52 Week High: $19.05 ; 52 Week Low: $1.60.

The stock opens at $1.85, after a previous close of $1.85. The stock reached a daily high of $1.94 and a low of $1.75, with a 52-week high of $19.05 and a 52-week low of $1.60.

Can Indians buy Perspective Therapeutics shares?

Yes, Indians can invest in the Perspective Therapeutics (CATX) from India.

With INDmoney, you can buy Perspective Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Perspective Therapeutics at zero transaction cost.

How can I buy Perspective Therapeutics shares from India?

It is very easy to buy Perspective Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Perspective Therapeutics (CATX) be purchased?

Yes, you can buy fractional shares of Perspective Therapeutics with INDmoney app.

What are the documents required to start investing in Perspective Therapeutics stocks?

To start investing in Perspective Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.